#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Bilastine in the treatment of allergic rhinitis –⁠ meta-analysis shows advantage of lower somnolence

A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine in the treatment of allergic rhinitis (AR), which includes symptoms of common rhinitis and allergic sensitization upon allergen exposure. The disease causes significant discomfort for patients and reduces their quality of life, which is why its control is essential for their daily functioning.
Source: Allergic Reactions 24. 5. 2022

News Comparison of the Effectiveness of Different Types of Toothbrushes in Orthodontic Patients

The aim of the study cited below was to evaluate the efficiency of a manual orthodontic brush, an electric toothbrush with an oscillating head, and a sonic toothbrush in controlling plaque, gingivitis, and interproximal bleeding in patients undergoing orthodontic treatment with fixed appliances and to compare their relative effectiveness.
Source: Dental Care 10. 5. 2023

News Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?

The nature of rheumatoid arthritis requires effective and long-term treatment. The current analysis of data from the long-term extension RA-BEYOND reveals the potential of baricitinib in maintaining low disease activity and remission with long-term use.
Source: Biological Treatment 12. 3. 2021

News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology

“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.
Source: Oncological Treatment 24. 3. 2022

News Expanded Hemodialysis as an Alternative to Hemodiafiltration

Expanded hemodialysis is a new type of therapy that effectively removes middle molecules from the blood of dialysis patients. The aim of the Spanish authors was to compare its efficiency with hemodiafiltration in terms of clearance of middle molecules in an open randomized clinical study.
Source: Chronic Kidney Disease 9. 12. 2021

News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis −⁠ True North Study Results

Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.
Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News First Effective Pharmacotherapy Modality for Negative Symptoms in Schizophrenia

Negative symptoms of schizophrenia significantly limit the quality of life and overall functioning of the patient. However, there have been no suitable medications to effectively suppress these symptoms until now. This is expected to change with the introduction of cariprazine into the antipsychotic armamentarium, as suggested by promising results from an analysis published last year in the journal European Psychiatry.
Source: Schizophrenia and Antipsychotics 21. 2. 2020

News Romiplostim in Life-Threatening Bleeding Situations −⁠ Case Reports

Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding due to a low platelet count. Some bleeding episodes can be life-threatening or fatal. Clinical experience suggests that in acute bleeding complications, whether in acute ITP or exacerbations of chronic ITP, early use of the thrombopoietin receptor agonist (TPO-RA) romiplostim can be beneficial. Japanese authors have described three case reports of severe diffuse alveolar hemorrhage (DAH) associated with various underlying conditions.
Source: Immune Thrombocytopenia 9. 5. 2023

News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD

Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.
Source: Modern Treatment of Diabetes 16. 9. 2022

News Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases

Genome sequencing provides doctors with more information about the causes of cancer diseases and changes the ways of treating tumors. Targeted therapy aimed at oncogenic mutations has brought patients longer survival and better clinical outcomes. Let's take a closer look at the advances and challenges of using genomics in oncology.
Source: Genetic Profile and Treatment of NSCLC 11. 11. 2021

News Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC

A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors –⁠ brigatinib, followed by lorlatinib –⁠ in real-world clinical practice.
Source: Non-Small Cell Lung Cancer 22. 12. 2022

News Cell-Based Implant as a Stable System for Biological Therapy Delivery

A team of scientists from Washington University in St. Louis focused on the possibility of delivering biological inhibitors for the treatment of rheumatoid arthritis using modified induced pluripotent stem cells. To verify the effectiveness of the therapy, they used a mouse model of rheumatoid arthritis, and their results represent progress in the development of rheumatoid arthritis treatment.
Source: Arthritis 19. 11. 2021

News MS in Children –⁠ An Overlooked Sister of Adult Diseases?

Multiple sclerosis is not just an adult disease. How common is it in children and how have current therapeutic possibilities advanced for this population both in our country and around the world?
Source: Multiple Sclerosis 6. 6. 2022

Journal articles The INKA Program –⁠ “tailor-made” obstetric analgesia

Author of the article: A. Pařízek Source: Česká gynekologie | 3/2014 18. 6. 2014

News Increased Sympathetic Activity in Patients with Masked Uncontrolled Hypertension

Not all hypertensive patients who have normal blood pressure readings in the doctor's office actually have controlled hypertension. Recent studies suggest that so-called masked uncontrolled hypertension may be linked to increased sympathetic activity.
Source: Cardiovascular Continuum 25. 1. 2021

News Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer

A pooled analysis of 25 studies with patients in the first line of treatment for metastatic colorectal cancer (mCRC) evaluated the prognostic and predictive significance of body mass index (BMI). Until its publication in 2015, only the adverse impact of low and high BMI on outcomes in patients with early stages of colorectal cancer was known.
Source: Colorectal Cancer 17. 5. 2020

News Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors

Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the control of bleeding in patients with congenital hemophilia A and inhibitors but also help to prevent such bleeding. A recent review article by experts from several European institutions provides an up-to-date view of the development, challenges, and future directions in the use of aPCC in the treatment of hemophilia.
Source: Hemophilia 2. 11. 2020

News Three tests to confirm the diagnosis of acquired hemophilia –⁠ infographic

Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.5 In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.4
Source: Acquired Hemophilia 8. 6. 2022

News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice

A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.
Source: Sartans in the Treatment of Hypertension 24. 10. 2022

Journal articles Sever bleeding one year after a cesarean section caused by placenta increta persistens

Author of the article: Š. Urbánek, H. Brádková, P. Beroušková, F. Farajpour Source: Česká gynekologie | 3/2012 1. 6. 2012

News The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney disease, heart failure, or high cardiovascular (CV) risk. A recent study published in the Clinical Journal of the American Society of Nephrology (CJASN) assessed whether long-term use of SGLT2i brings benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4i, i.e., gliptins) in diabetics without documented CV or renal disease using data from a large Israeli database.
Source: Diabetes 5. 12. 2023

News ESC 2022: What Current Insights Say About the Role of Dabigatran in Stroke Prevention with Atrial Fibrillation and Comorbidities

The risk of atrial fibrillation (AF) increases with age as risk factors accumulate and comorbidities arise. What do current data from randomized clinical trials and registries show about stroke prevention (SP) in the context of concurrent AF and some other chronic diseases? This was the focus of one of the symposia at this year's European Society of Cardiology (ESC) Congress.
Source: Anticoagulant Treatment 13. 10. 2022

News Can the Treatment of Hypertension Prevent Recurrence of Atrial Fibrillation?

Atrial fibrillation (Afib) is the most common serious heart rhythm disorder and is responsible for a significant portion of deaths in the population. Hypertension is the most common and potentially modifiable risk factor for Afib. A newly published meta-analysis compares the effect of angiotensin receptor antagonism and calcium channel blockade on Afib recurrence in patients with hypertension and Afib.
Source: Sartans in the Treatment of Hypertension 3. 12. 2021

News Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?

An article by French authors published in January this year in the journal Multiple Sclerosis and Related Disorders evaluated the effect of teriflunomide on fatigue in patients with multiple sclerosis in real-world practice.
Source: Multiple Sclerosis 19. 4. 2021

News Alarming Data on Prevalence and Insufficient Treatment of Hypertension in Working Age −⁠ Another Underestimated 'Civilization Epidemic'?

The National Cardiology Information System (NKIS), developed by the Czech Society of Cardiology in collaboration with the Institute of Health Information and Statistics (ÚZIS), has provided the first data on the prevalence of hypertension in the Czech population. It revealed that even the treatment of a significant risk factor for cardiovascular diseases –⁠ hypertension –⁠ is not well managed in the Czech Republic. About 40% of patients with hypertension do not have regular preventive check-ups with their general practitioner, while 40% of hypertensive patients are simultaneously of working age.
Source: Risk factors of cardiovascular diseases 10. 6. 2024

1 20 21 22 23 24 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#